Related Experiment Videos

MOZ is fused to p300 in an acute monocytic leukemia with t(8;22)

M Chaffanet1, L Gressin, C Preudhomme

  • 1Laboratoire d'Oncologie Moléculaire, INSERM U119, Marseille, France.

Insights

A novel gene fusion between the monocytic leukemia zinc finger protein (MOZ) and adenoviral E1A-associated protein p300 (p300) was identified in acute monocytic leukemia. This MOZ-p300 fusion creates an abnormal co-activator, potentially driving leukemogenesis.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Acute monocytic leukemia (AML M5) is a subtype of leukemia.
  • Chromosomal translocations are common in leukemia and can lead to gene fusions.
  • The MOZ and p300 genes encode acetyltransferases involved in transcriptional regulation.

Purpose of the Study:

  • To investigate a novel gene fusion in acute monocytic leukemia.
  • To characterize the molecular consequences of a t(8;22) translocation.
  • To identify potential drivers of leukemogenesis.

Main Methods:

  • Double-color fluorescence in situ hybridization (FISH) using specific probes for MOZ and p300 genes.
  • Southern blot analysis to detect MOZ gene rearrangement.
  • Reverse transcription-polymerase chain reaction (RT-PCR) to clone and identify fusion transcripts.

Main Results:

  • A reciprocal translocation t(8;22)(p11;q13) was identified in two patients with AML M5.
  • FISH analysis confirmed the rearrangement and fusion of MOZ and p300 genes.
  • Fusion transcripts involving MOZ and p300 were detected and cloned, indicating their expression.

Conclusions:

  • A novel MOZ-p300 gene fusion resulting from the t(8;22) translocation has been identified in acute monocytic leukemia.
  • This fusion generates an abnormal transcriptional co-activator.
  • The MOZ-p300 fusion protein may play a critical role in the development of leukemia.

Related Concept Videos